Filing Flows › Comparisons › NRIX vs INSM
Nurix Therapeutics vs Insmed: NRIX and INSM compared
Nurix Therapeutics is the larger company: $673M of revenue in its latest quarter (Q3 FY26) against $524M for Insmed (Q3 2026). Nurix Therapeutics is growing faster (85× against +268% a year earlier). Nurix Therapeutics is more profitable, with an operating margin of 83.1% against -17.0%.
Where the money goes: NRIX and INSM
Nurix Therapeutics (NRIX) · Q3 FY26
Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%, net earnings $550M, operating cash flow $616M. The chart follows the revenue to costs, profit and cash.
Insmed (INSM) · Q3 2026
Insmed, Q3 2026: revenue $524M (+268% year over year), operating margin -17.0%, net loss $100M, operating cash flow −$36.5M. The chart follows the revenue to costs, profit and cash.
| Nurix Therapeutics (NRIX) | Insmed (INSM) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 2026 |
| Revenue | $673M | $524M |
| Revenue growth, Y/Y | 85× | +268% |
| Operating margin | 83.1% | -17.0% |
| Net earnings | $550M | −$100M |
| Net margin | 81.7% | -19.1% |
| Operating cash flow | $616M | −$36.5M |
| Free cash flow | $614M | — |
| Market value | $1.8B | $25.0B |
| P/E | 6.7× | — |
| Analysts’ mean target | $33.38 | $194.18 |
Where the revenue comes from
Nurix Therapeutics
- License revenue: $653M (97%)
- Collaboration revenue: $19.9M (3%)
Insmed
- BRINSUPRI: $400M (76%)
- ARIKAYCE: $124M (24%)
Questions
Which is bigger, Nurix Therapeutics or Insmed?
Nurix Therapeutics is the larger company: $673M of revenue in its latest quarter (Q3 FY26) against $524M for Insmed (Q3 2026).
Is Nurix Therapeutics or Insmed growing faster?
Nurix Therapeutics is growing faster (85× against +268% a year earlier).
Which is more profitable, Nurix Therapeutics or Insmed?
Nurix Therapeutics is more profitable, with an operating margin of 83.1% against -17.0%.
More: Nurix Therapeutics earnings · how Nurix Therapeutics makes money · Insmed earnings · how Insmed makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 13, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.